Monday looks likely to be a tough day for BioAge Labs, a US biopharma developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. 9 December 2024
Dutch biotech Citryll, which is focused on treating immune-mediated inflammatory diseases by targeting neutrophil extracellular traps (NETs), today announced the successful closing of an oversubscribed 85 million euros ($89.8 million) Series B fundraise. 9 December 2024
Ophthalmic gene therapy company Beacon Therapeutics Holdings has announced the presentation of three-month interim safety and efficacy results of AGTC-501 (laruparetigene zovaparvovec; laru-zova) in the Phase II DAWN trial in patients with X-linked retinitis pigmentosa (XLRP at the FLORetina-ICOOR Meeting 2024 in Florence, Italy. 6 December 2024
Menlo Park-based Nuvig Therapeutics has raised $161 million in a series B financing round co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities, and Norwest Venture Partners. 6 December 2024
Privately-held Muna Therapeutics, a Danish biotech focused on neurodegenerative diseases, has announced a research alliance with UK pharma major GSK to identify and validate novel drug targets for the treatment of Alzheimer’s disease. 5 December 2024
Germany-headquartered CNS drug specialist Neuraxpharm today revealed that UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the use of ublituximab (150mg concentrate for solution for infusion) in the treatment of relapsing-remitting multiple sclerosis (RRMS). 5 December 2024
The US Food and Drug Administration (FDA) yesterday granted accelerated approval to Bizengri (zenocutuzumab-zbco; Zeno) from Dutch firm Merus NV, whose shares edged up 1.8% to $46.32 on the news. 5 December 2024
Massachusetts, USA-based clinical stage biotech Rgenta Therapeutics, which is developing a new class of oral small molecules targeting RNA for oncology and neurological disorders, announced today that it has entered into a multi-year, multi-target strategic research alliance with the UK’s GSK. 4 December 2024
Shares of US precision medicines firm Relay Therapeutics closed down 6% at $4.39 yesterday after announced a licensing deal for its lirafugratinib. 4 December 2024
Privately-held Dewpoint Therapeutics, a Boston, USA, biotech developing therapeutics by targeting biomolecular condensates, has entered into a strategic research collaboration with Japan’s Mitsubishi Tanabe Pharma Corporation (MTPC). 4 December 2024
Chinese biotech Duality Biologics yesterday revealed that it has entered into an exclusive option agreement with UK pharma major GSK for a potentially best-in-class ADC candidate, DB-1324. 4 December 2024
Boston-based AI Proteins, a biotech that uses computational de novo protein design to create therapeutic miniproteins, has entered a research collaboration and option agreement with US pharma major Bristol Myers Squibb. 4 December 2024
Refoxy Pharmaceuticals has raised 9.1 million euros ($10 million) in seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), with support from Apollo Health Ventures and others. 4 December 2024
Japanese drugmaker Ono Pharmaceutical has entered into a drug discovery collaboration agreement with privately-held Canadian firm Congruence Therapeutics. 4 December 2024
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Danish drug developer Antag Therapeutics, which is pioneering novel treatments for obesity, today announced the closing of an 80 million euros ($83.8 million) Series A financing. 4 December 2024
Maze Therapeutics, a California-based biotech, has raised $115 million in a series D financing round co-led by Frazier Life Sciences and Deep Track Capital. 4 December 2024
US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target. 3 December 2024
US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant Novartis in frontline metastatic breast cancer. 3 December 2024
USA-based UroGen Pharma, a biotech developing and commercializing innovative solutions that treat urothelial and specialty cancers, closed 45% lower Wednesday. 22 May 2025
Privately-held US genome-scale drug discovery company Orionis Biosciences has announced a second multi-year collaboration with Genentech, a subsidiary of Roche , to discover small-molecule monovalent glue medicines for novel and challenging targets in oncology. 22 May 2025
Swiss reproductive and women’s health medicines specialist ReproNovo today announced the successful closing of a $65 million Series A financing round, which will be used to advance its pipeline of multiple Phase II programs. 21 May 2025
North Carolina, USA-based vTv Therapeutics has announced that screening has been reinitiated in the company’s CATT1 Phase III trial investigating cadisegliatin as an adjunctive treatment of type 1 diabetes (T1D). 21 May 2025
US biotechs Protagenic Therapeutics and Phytanix Bio have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction. 21 May 2025
UK-based Juvenescence, a clinical stage AI-enabled biotech company, has secured a total of $76 million in the first-close of a Series B-1 round, led by cornerstone investor M42, with follow-on investments from existing investors. 21 May 2025
Cambridge, USA-based Apnimed today announced positive top-line results from its pivotal Phase III SynAIRgy clinical trial evaluating the efficacy and safety of its lead candidate AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in adults living with mild, moderate and severe OSA, and across all weight classes. 20 May 2025
German vaccine pioneer BioNTech today revealed that its UK subsidiary has signed a grant agreement with the UK government to broaden the company’s R&D activities for innovative medicines in the UK. 20 May 2025
Swiss gene-editing specialist CRISPR Therapeutics and San Diego, USA-based Sirius Therapeutics, which is developing innovative small interfering RNA (siRNA) therapies, announced a strategic partnership to develop and commercialize siRNA therapies. 20 May 2025
US human genetics biotech 23andMe today revealed it has entered into a definitive agreement for the sale of the company to Regeneron Pharmaceutical, whose shares climbed 2% following the announcement 19 May 2025
USA-based rare disease company Applied Therapeutics saw its shares rise nearly 23% to $0.60 on Friday, ahead of a planned presentation on its lead candidate, govorestat, at the Peripheral Nerve Society (PNS) 2025 Annual Meeting, being held May 17-20 in Edinburgh, Scotland. 19 May 2025
California’s BioMarin Pharmaceutical is to acquire Inozyme Pharma or $4 per share in an all-cash transaction for a total consideration of approximately $270 million. 16 May 2025
Telomir Pharmaceuticals, a US age-reversal science-based biotech, has identified Telomir-Ag2 as a novel drug candidate for the treatment of bacterial infections, including those caused by drug-resistant pathogens. 16 May 2025
US biopharma Biohaven has been told by the US Food and Drug Administration (FDA) that the agency is extending the PDUFA date for the company’s troriluzole new drug application (NDA) for the treatment of spinocerebellar ataxia (SCA) by three months. 16 May 2025